PT1601698E - Conjugado polipeptídico fisiologicamente activo com uma vida média prolongada in vivo - Google Patents
Conjugado polipeptídico fisiologicamente activo com uma vida média prolongada in vivo Download PDFInfo
- Publication number
- PT1601698E PT1601698E PT04720540T PT04720540T PT1601698E PT 1601698 E PT1601698 E PT 1601698E PT 04720540 T PT04720540 T PT 04720540T PT 04720540 T PT04720540 T PT 04720540T PT 1601698 E PT1601698 E PT 1601698E
- Authority
- PT
- Portugal
- Prior art keywords
- life
- prolonged
- physiologically active
- active polypeptide
- vivo half
- Prior art date
Links
- 238000001727 in vivo Methods 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030015744 | 2003-03-13 | ||
KR20030036408 | 2003-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1601698E true PT1601698E (pt) | 2009-06-17 |
Family
ID=36096009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT04720540T PT1601698E (pt) | 2003-03-13 | 2004-03-13 | Conjugado polipeptídico fisiologicamente activo com uma vida média prolongada in vivo |
Country Status (16)
Country | Link |
---|---|
US (2) | US20050176108A1 (pt) |
EP (1) | EP1601698B1 (pt) |
JP (1) | JP4481980B2 (pt) |
KR (1) | KR100567902B1 (pt) |
CN (2) | CN1761684A (pt) |
AT (1) | ATE425188T1 (pt) |
AU (1) | AU2004220163B2 (pt) |
BR (1) | BRPI0408331B8 (pt) |
CA (1) | CA2519059C (pt) |
DE (1) | DE602004019887D1 (pt) |
ES (1) | ES2324298T3 (pt) |
HK (1) | HK1177465A1 (pt) |
IL (1) | IL170685A (pt) |
PT (1) | PT1601698E (pt) |
RU (1) | RU2312868C2 (pt) |
WO (1) | WO2004081053A1 (pt) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
JP4870569B2 (ja) | 2003-11-13 | 2012-02-08 | ハンミ ホールディングス カンパニー リミテッド | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
MXPA06015234A (es) * | 2004-06-30 | 2007-11-22 | Nektar Therapeutics Al Corp | Conjugados de fraccion polimero-factor ix. |
LT3130601T (lt) * | 2004-11-12 | 2020-09-10 | Bayer Healthcare Llc | Į vietą nukreipta fviii modifikacija |
PT1835938E (pt) | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
EP3144675A1 (en) | 2005-04-28 | 2017-03-22 | Ventana Medical Systems, Inc. | Enzymes conjugated to antibodies via a peg heterobifuctional linker |
AU2006250068A1 (en) * | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-IGG fusion |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
JP2009513627A (ja) * | 2005-10-27 | 2009-04-02 | ペプトロン カンパニー リミテッド | 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法 |
US20070117153A1 (en) | 2005-11-23 | 2007-05-24 | Christopher Bieniarz | Molecular conjugate |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
AU2007245190B2 (en) | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
ES2889920T3 (es) | 2006-06-14 | 2022-01-14 | Csl Behring Gmbh | Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
US8742079B2 (en) | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
EP2214700A4 (en) * | 2007-11-02 | 2012-08-22 | Janssen Biotech Inc | HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES |
JP5546107B2 (ja) * | 2008-04-17 | 2014-07-09 | 国立大学法人宇都宮大学 | RNAウイルスBmMLV陰性カイコ培養細胞株 |
EP2444491B1 (en) | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
WO2010074082A1 (ja) * | 2008-12-24 | 2010-07-01 | 塩野義製薬株式会社 | バソヒビン修飾体 |
CN101585864B (zh) * | 2009-01-05 | 2011-11-09 | 天津派格生物技术有限公司 | 柱层析粒细胞集落刺激因子氮端定点偶联方法及其产物 |
DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
BRPI1013626B8 (pt) | 2009-03-20 | 2021-05-25 | Hanmi Holdings Co Ltd | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
EP2525787B1 (en) | 2010-01-19 | 2017-03-15 | Hanmi Science Co., Ltd. | Liquid formulations for long-acting g-csf conjugate |
MX2012008453A (es) * | 2010-01-19 | 2012-11-21 | Hanmi Science Co Ltd | Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada. |
EP2542572B1 (en) * | 2010-03-02 | 2015-05-06 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
CA2818583A1 (en) * | 2010-11-19 | 2012-05-24 | Venus Remedies Limited | Novel conjugates for targeted drug delivery |
KR101309566B1 (ko) * | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
DK2665814T3 (en) | 2011-01-20 | 2017-09-11 | Protalix Ltd | NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS |
CN102309765B (zh) * | 2011-02-28 | 2013-10-16 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段作为载体的长效抗凝多肽及其制备方法 |
RU2502803C2 (ru) * | 2011-05-20 | 2013-12-27 | Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") | ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia, НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНОВ, БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ НЕАКТИВНОГО ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА ИЛИ ЕЕ МУТЕИНА, СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТОВ ПОЛИЭТИЛЕНГЛИКОЛЯ И РЕКОМБИНАНТНОГО МУТЕИНА ДНКазы I ЧЕЛОВЕКА, ФЕРМЕНТАТИВНО АКТИВНЫЙ КОНЪЮГАТ МУТЕИНА РЕКОМБИНАНТНОЙ ДНКазы I ЧЕЛОВЕКА |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
CN102807619B (zh) * | 2011-06-03 | 2016-08-03 | 北京韩美药品有限公司 | 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物 |
CN102313773B (zh) * | 2011-07-29 | 2013-11-20 | 首都师范大学 | 一种鉴定蛋白质中半胱氨酸数量的方法及其应用 |
RU2622077C2 (ru) * | 2011-09-05 | 2017-06-09 | Ханми Сайенс Ко., Лтд. | Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
CN103172745A (zh) * | 2011-12-21 | 2013-06-26 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段的长效人内皮抑素 |
KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
SG11201404885RA (en) | 2012-02-15 | 2014-09-26 | Amunix Operating Inc | Factor viii compositions and methods of making and using same |
US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US10064951B2 (en) | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
CN103235136B (zh) * | 2012-04-28 | 2014-12-10 | 淄博高新区云桥生物技术研究所 | 蛋白质类药物三维构像的抗体阵序列检测方法 |
EP2857417B1 (en) * | 2012-06-05 | 2018-02-14 | CJ Healthcare Corporation | Highly glycosylated long-acting human growth hormone protein and production method for same |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
SG10201602801YA (en) | 2012-11-06 | 2016-05-30 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
CN103257237B (zh) * | 2013-05-09 | 2015-05-20 | 中国农业大学 | 一种食品中过敏原的体外检测方法 |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
CN105848645A (zh) | 2013-09-27 | 2016-08-10 | 韩美药品株式会社 | 持续型人生长激素制剂 |
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
EP3098235A4 (en) * | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
CN107580499A (zh) * | 2015-03-17 | 2018-01-12 | 欧姆尼奥克斯公司 | 通过蛋白质介导的o2递送调节肿瘤免疫性 |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
RU2656140C2 (ru) * | 2016-11-14 | 2018-05-31 | Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России | Способ получения гибридного белка, состоящего из рекомбинантного белка аналога интерферона гамма, конъюгированного с олигосахаридом |
JP2020535199A (ja) * | 2017-09-29 | 2020-12-03 | ハンミ ファーマシューティカル カンパニー リミテッド | 効力が向上した持続性タンパク質結合体 |
CN108164700B (zh) * | 2017-12-27 | 2020-05-08 | 暨南大学 | 一种用于输送疏水性药物的活性氧响应性纳米载体及其制备方法 |
GB201801902D0 (en) * | 2018-02-06 | 2018-03-21 | Stichting Katholieke Univ | Immunomodulatory nanofilaments |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
US11267858B2 (en) * | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
US20240132566A1 (en) * | 2019-10-16 | 2024-04-25 | Jcr Pharmaceuticals Co., Ltd. | Method for producing fusion protein of serum albumin and growth hormone |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
WO2021261712A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE427505B (sv) * | 1977-03-04 | 1983-04-11 | Pharmacia Diagnostics Ab | Reagens till anvendning vid immunkemiska bestemningsmetoder |
US4487325A (en) | 1982-07-06 | 1984-12-11 | Owens-Illinois, Inc. | Crown closures and containers |
GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
US5216130A (en) * | 1990-05-17 | 1993-06-01 | Albany Medical College | Complex for in-vivo target localization |
EP0513332A4 (en) * | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
EP0575545B1 (en) * | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
ATE181961T1 (de) * | 1991-04-17 | 1999-07-15 | Medisup Int Nv | Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone |
EP0622082A4 (en) * | 1992-07-28 | 1996-12-04 | Toray Industries | IMMUNOCOMPLEX. |
ATE267255T1 (de) * | 1995-12-27 | 2004-06-15 | Genentech Inc | Ob proteinderivate mit verlängerter halbwertzeit |
DE60035871T2 (de) | 1999-05-19 | 2008-06-05 | Merck Patent Gmbh | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
US6596849B1 (en) * | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
ES2317843T3 (es) | 1999-07-13 | 2009-05-01 | Bolder Biotechnology, Inc. | Proteinas de fusion de eritropoyetina-inmunoglobulina. |
WO2001023430A2 (en) * | 1999-09-30 | 2001-04-05 | Icos Corporation | Human chitinase immunoglobulin fusion proteins |
WO2003049684A2 (en) * | 2001-12-07 | 2003-06-19 | Centocor, Inc. | Pseudo-antibody constructs |
WO2004024889A2 (en) | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
-
2003
- 2003-09-09 US US10/659,195 patent/US20050176108A1/en not_active Abandoned
-
2004
- 2004-03-12 KR KR1020040016826A patent/KR100567902B1/ko active IP Right Grant
- 2004-03-13 BR BRPI0408331A patent/BRPI0408331B8/pt active IP Right Grant
- 2004-03-13 RU RU2005128504/13A patent/RU2312868C2/ru active
- 2004-03-13 WO PCT/KR2004/000535 patent/WO2004081053A1/en active Application Filing
- 2004-03-13 CA CA2519059A patent/CA2519059C/en not_active Expired - Lifetime
- 2004-03-13 PT PT04720540T patent/PT1601698E/pt unknown
- 2004-03-13 AU AU2004220163A patent/AU2004220163B2/en not_active Expired
- 2004-03-13 AT AT04720540T patent/ATE425188T1/de not_active IP Right Cessation
- 2004-03-13 JP JP2006500659A patent/JP4481980B2/ja not_active Expired - Lifetime
- 2004-03-13 DE DE602004019887T patent/DE602004019887D1/de not_active Expired - Lifetime
- 2004-03-13 CN CNA2004800068263A patent/CN1761684A/zh active Pending
- 2004-03-13 EP EP04720540A patent/EP1601698B1/en not_active Expired - Lifetime
- 2004-03-13 ES ES04720540T patent/ES2324298T3/es not_active Expired - Lifetime
- 2004-03-13 CN CN201210217939.4A patent/CN102757505B/zh not_active Expired - Lifetime
-
2005
- 2005-09-06 IL IL170685A patent/IL170685A/en active IP Right Grant
-
2009
- 2009-10-22 US US12/603,757 patent/US8163889B2/en not_active Expired - Fee Related
-
2013
- 2013-02-19 HK HK13102067.9A patent/HK1177465A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BRPI0408331A (pt) | 2006-03-21 |
EP1601698A1 (en) | 2005-12-07 |
BRPI0408331B1 (pt) | 2019-09-17 |
US8163889B2 (en) | 2012-04-24 |
ES2324298T3 (es) | 2009-08-04 |
JP2007528346A (ja) | 2007-10-11 |
RU2005128504A (ru) | 2006-03-10 |
CN1761684A (zh) | 2006-04-19 |
KR100567902B1 (ko) | 2006-04-04 |
CN102757505A (zh) | 2012-10-31 |
CA2519059A1 (en) | 2004-09-23 |
EP1601698B1 (en) | 2009-03-11 |
JP4481980B2 (ja) | 2010-06-16 |
AU2004220163A1 (en) | 2004-09-23 |
IL170685A0 (en) | 2009-02-11 |
CA2519059C (en) | 2012-12-18 |
EP1601698A4 (en) | 2006-05-03 |
AU2004220163B2 (en) | 2008-01-31 |
HK1177465A1 (zh) | 2013-08-23 |
BRPI0408331A8 (pt) | 2016-06-07 |
CN102757505B (zh) | 2015-10-07 |
US20050176108A1 (en) | 2005-08-11 |
US20100105869A1 (en) | 2010-04-29 |
BRPI0408331B8 (pt) | 2021-05-25 |
ATE425188T1 (de) | 2009-03-15 |
WO2004081053A1 (en) | 2004-09-23 |
DE602004019887D1 (de) | 2009-04-23 |
IL170685A (en) | 2012-05-31 |
RU2312868C2 (ru) | 2007-12-20 |
KR20040081378A (ko) | 2004-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1177465A1 (zh) | 具有延長的體內半衰期的生理學活性多肽綴合物 | |
MXPA05007210A (es) | Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo. | |
DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
DE60039629D1 (de) | Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand | |
TW200711657A (en) | Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin | |
TNSN00206A1 (en) | Method for treating diabetes | |
MXPA05013564A (es) | Proteinas de fusion. | |
MXPA05007470A (es) | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. | |
DE60109949D1 (de) | Chirurgischer kopfrahmen mit weichen kontaktauflagen für stereotaktisches system | |
ATE432689T1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
DE69804974T2 (de) | Opioid-konjugate mit endogenen trägerproteinen | |
LT2002063A (en) | Low-dose metformin and gliburide combinations for treating diabetes | |
WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
NO20042055L (no) | Tymosinalfa 1-peptid/polymerkonjugater | |
SE9703775L (sv) | Framställning av sterial lösningar som innehåller glukos | |
HUP0400340A2 (hu) | Polipeptidek immunogenitásának csökkentésére szolgáló eljárások | |
CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
MD1474F1 (en) | Method of treatment of the puerperal endometritis | |
TR200301916T4 (tr) | Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem. |